Circulating miRNA-21 and miRNA-23a Expression Signature as Potential Biomarkers for Early Detection of Non-Small-Cell...

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Discovery

Background:

• Lung cancer (LC) has a poor prognosis, necessitating improved diagnostic and therapeutic strategies.
• Cell-free microRNAs (miRNAs) in plasma show promise as cancer biomarkers.
• The clinical utility of miR-21 and miR-23a in non-small cell lung cancer (NSCLC) requires investigation.

Purpose of the Study:

• To identify differentially expressed miRNAs in NSCLC patient plasma.
• To evaluate miR-21 and miR-23a as potential biomarkers for early lung cancer detection.
• To assess the association of these miRNAs with clinicopathological parameters in NSCLC.

Main Methods:

• A case-control study involving 45 NSCLC patients and 40 healthy controls.
• Quantitative reverse transcription polymerase chain reaction (qRT-PCR) to measure plasma miR-21 and miR-23a levels.
• Statistical analysis to compare miRNA expression and correlate with clinicopathological features.

Main Results:

• Plasma miR-21 and miR-23a were significantly upregulated in NSCLC patients compared to controls (P<0.0001).
• Elevated miRNA levels correlated with disease grade, tumor size, and distant metastasis.
• A positive correlation was found between plasma miR-21 and miR-23a expression (r=0.784, P<0.01).

Conclusions:

• miR-21 and miR-23a may play an oncogenic role in lung cancer.
• These miRNAs show potential as prognostic factors and diagnostic biomarkers for NSCLC.
• Further large-scale prospective studies are recommended to validate these findings.